Latest Features
Experts discuss strategies to reduce the maternal mortality gap by implementing implicit bias training and reevaluating clinical guidelines and algorithms.
Annual pay, growth potential, cost of living are among the important considerations.
These are the clinical trials that led to the FDA’s approval of aducanumab and lecanemab for early AD, plus, the concerns that loom.